BioMarin and Ascendis Pharma have reached a binding settlement to resolve all global patent disputes concerning the drug Yuviwel. Under the agreement, Ascendis will pay BioMarin significant royalties on Yuviwel sales, granting Ascendis a full license to BioMarin's patents, which is a material financial and operational development for both companies.
BioMarin and Ascendis Pharma have ended their global patent disputes over Yuviwel, a key drug for achondroplasia. This settlement is significant because it provides BioMarin with a new revenue stream through substantial royalty payments (20% in the U.S., 18% internationally) on Yuviwel sales, which could positively impact its financial outlook. For Ascendis, while it means ongoing royalty payments, it removes the uncertainty and cost of protracted legal battles, securing its ability to market Yuviwel globally and potentially expanding its indications. Short-term, BioMarin sees an immediate financial upside, while Ascendis gains clarity and stability for its flagship product. Long-term, this allows both companies to focus on R&D and market expansion without legal distractions, with Ascendis's projected 2026 operating cash flow and 2030 revenue targets now more secure, albeit with a portion allocated to BioMarin.